Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook




 

Gene therapy nears approval as European regulator makes recommendation

30 July 2012

By Dr Rosie Gilchrist

Appeared in BioNews 667

The European Medicines Agency (EMA) has recommended European Union market approval for a gene therapy, Glybera, to treat patients with severe cases of a rare genetic condition called lipoprotein lipase deficiency (LPLD). If the treatment is approved by the European Commission, which usually follows the recommendations of the EMA, Glybera will be the first commercially available gene therapy in Europe and the USA.

'This is a watershed moment. Gene therapy holds incredible promise for people, especially those with rare disease. It paves the way for the approval of other treatments of this kind', said Dr Tim Coté, former director of the US Food and Drug Administration's office of orphan products development.

Due to mutations in the LPL gene, patients with LPLD lack the necessary enzyme to break down fat from digested food, which can cause fat globules to build up in the blood resulting in severe abdominal pain and pancreatitis. The only way to manage the disease at present is for patients to control the fat content in their diet. Glybera works by using a virus vector to introduce a working copy of the gene.

Jörn Aldag, chief executive at UniQure, the company that is developing the drug, said: 'Now, for the first time, a treatment exists for these patients that not only reduces this risk, but also has a multi-year beneficial effect after just one treatment'.

The approval of Glybera has not been without problems. LPLD is very rare affecting one or two people per million, so it is difficult to assess the risks and safety of the drug in the usual way. Glybera originally received a negative response from the EMA, and the recent recommendation is only for use in patients with a severe form of the disease.

Gene therapy is aimed at patients with genetic diseases and essentially replaces their faulty genes with working ones. The only other commercially available gene therapy is Gendicine, which was approved for the Chinese market in 2004 to treat cancer.

Gene therapy has received bad press in the past after the trial of a drug to treat children with severe combined immunodeficiency was suspended due to some participants developing leukaemia. Another setback to the development of gene therapies was the death of a participant after he reacted adversely to the injected virus in a gene therapy trial.

SOURCES & REFERENCES
Nature News | 20 July 2012
 
European Medicines Agency | 20 July 2012
 
New Scientist | 24 July 2012
 
UniQure (press release) | 20 July 2012
 
BBC News | 20 July 2012
 
Guardian | 20 July 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

06 June 2016 - by Rachel Reeves 
The European Commission has granted marketing authorisation for a gene therapy to treat children with an extremely rare, life-threatening genetic disorder...
01 December 2014 - by Arit Udoh 
Glybera, the first gene therapy to go on sale in Europe, is set to cost €1.1m (£870,000) per patient, making it the world's most expensive drug...
30 June 2014 - by Emma Hughes 
In Wales, the subject of access to medicines has recently been in the spotlight. We are calling on the National Assembly to review the use of the 'exceptionality' rule in determining whether a patient can access a treatment through the IPFR process...
05 November 2012 - by Dr Lucy Spain 
The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....
10 September 2012 - by Holly Rogers 
Scientists have restored the sense of smell in mice using a gene therapy designed to repair the cilia - hair-like formations on nasal cells that are important in olfaction...

11 June 2012 - by Dr Tamara Hirsch 
Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...
26 July 2009 - by Dr Rebecca Robey 
Scientists have used two new techniques to fix defects in lung cells from people with cystic fibrosis, raising hope for new treatments for the disease in the future. The first study, published in the journal Plos Biology, used a gene therapy technique to treat the cells, whilst the second study, published in the American Journal of Respiratory Cell and Molecular Biology, used a drug called miglustat....
07 July 2004 - by BioNews 
Terminally ill cancer patients from Europe and America are travelling to China to receive a new gene-based drug, the world's first commercially available gene therapy treatment. Chinese biotech firm SiBiono Genetech launched the drug in January, initially for the treatment of head and neck squamous cancers (a type of skin...
01 December 2003 - by BioNews 
A Chinese biotech firm has been granted permission to market the world's first commercial gene therapy medicine, New Scientist magazine reports. The country's medicines authority has approved Gendicine, a new cancer treatment, after promising results in a clinical trial. It will be launched in January by the firm SiBiono GeneTech...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation